Clear Search sequence regions
Bookmark Forward

QuickView for Insulin Aspart (compound)


DrugBank
Identification
Name: Insulin Aspart
Name (isomeric): DB01306
Drug Type: biotech
Description: Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.
Synonyms:
INA-X14; Aspart Insulin; Insulin, Asp(B28); B28-Aspart-Insulin; Aspart; Insulin X14
Brand: NovoRapid, NovoRapid Penfill, NovoLog, Novolog Penfill, Novolog FlexPen
Brand name mixture:
Novolog Mix 70/30 FlexPen(insulin aspart 30 units/ml + insulin aspart protamine 70 units/ml), Novolog Mix 70/30 Penfill(insulin aspart 30 units/ml + insulin aspart protamine 70 units/ml), NovoMix 30(insulin aspart 30 units/ml + insulin aspart protamine 70 units/ml), NovoLog Mix 70/30(insulin aspart 30 units/ml + insulin aspart protamine 70 units...
show more »
Category: Hypoglycemic Agents, Antidiabetic
CAS number: 116094-23-6
Pharmacology
Indication: For the treatment of Type 1 or 2 diabetes mellitus. Should normally be used in conjunction with an intermediate or long-acting insulin.
Pharmacology:
Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Postprandial insulin spikes are responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular ...
show more »
Mechanism of Action:
Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates ...
show more »
Absorption: Rapidly absorbed following subcutaneous administration.
Protein binding: 0-9%
Half Life: 81 minutes
Clearance: 1.2 l/h/kg [healthy Caucasian male]
Toxicity: Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
FenfluramineFenfluramine increases the effect of insulin
AcebutololThe beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
EsmololThe beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
ClofibrateIncreases the effect of insulin
BisoprololThe beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
show more »

Targets


Enzymes